The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a Valproate National Patient Safety Alert in advance of new regulatory measure being introduced from January 2024.

The alert calls on Integrated Care Boards (in England) and Health Boards (in Scotland and Wales) to designate a new or existing group to prepare for and co-ordinate the implementation of the new regulatory measures for oversight of prescribing valproate to new patients and existing female patients.

The General Pharmaceutical Council (GPhC) said:

“Pharmacy teams should continue to dispense valproate. They should be prepared to discuss the current warnings and upcoming measures with their patients.”

Further information is available on the MHRA website.


Insight Works Training

Disclaimer: The accuracy and information of news stories published on this website is accurate on the date of publishing. We endeavour to update stories if information change. You can contact us with change and update requests. Where possible, we will link to sources. Content on this website is for guidance purposes only. We cannot accept any responsibility or liability whatsoever for any action taken, or not taken. You should seek the appropriate legal advice having regard to your own particular circumstances.